Gentian Diagnostics ASA (GENT)

Overview

Gentian Diagnostics ASA is a pioneering firm specializing in the research, development, and manufacturing of biochemical reagents crucial for medical diagnostics and research on a global scale. Established in 2001 and headquartered in Moss, Norway, Gentian Diagnostics stands at the forefront of innovation within the medical diagnostics field. Their expertise lies in creating in-vitro diagnostic reagents compatible with clinical chemistry analyzers, catering to a wide range of medical and research applications. The company’s product portfolio addresses various critical healthcare needs, including inflammation detection, renal function diagnosis, nutritional deficiency assessments, and veterinary health, among others. Additionally, Gentian Diagnostics plays a vital role in responding to global health crises, as shown in their development of diagnostic solutions for infectious diseases like COVID-19.

Products and Services

• Gentian Circulating Calprotectin Immunoassay: A cutting-edge turbidimetric immunoassay designed for the accurate measurement of calprotectin levels in plasma and serum. This test is instrumental in detecting and assessing inflammation, providing essential insights into the patient's inflammatory status.
• Gentian Cystatin C Immunoassay Test Kit: This test kit serves as a reliable marker for glomerular filtration rate, aiding in the diagnosis and therapeutic monitoring of renal function. It is a critical tool for healthcare providers in managing patients with kidney-related conditions.
• Gentian Retinol-Binding Protein Immunoassay: This assay facilitates the detection of retinol-binding protein in human serum and plasma, offering valuable data for diagnosing nutritional deficiencies and monitoring vitamin A statuses.
• Canine CRP Immunoassay Test Kit: A specialized particle-enhanced turbidimetric immunoassay designed for the quantitative determination of canine C-reactive protein in dog plasma and serum. This test is pivotal in diagnosing and monitoring inflammation in canine patients, highlighting the company’s commitment to veterinary health.
• SARS-CoV-2 Total Antibody Immunoassay: A comprehensive quantitative antibody test that captures the full immune response by detecting antibodies targeting the S1-subunit of the virus. This assay is critical in assessing the immune status of individuals exposed to or recovered from COVID-19, contributing to public health efforts in managing the pandemic.
• NT-proBNP Immunoassay: Currently in the product development phase, this immunoassay is being designed as an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure. It represents the company’s ongoing commitment to addressing critical healthcare challenges through innovation.